ArticleISRN pharmacology2012
Biomarkers in Alzheimer's disease: a review.
Article in ISRN pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- c-Triadem: A constrained, explainable deep learning model to identify novel biomarkers in Alzheimer's disease.PloS one · 2025Article
- Biomarkers: Role and Scope in Neurological Disorders.Neurochemical research · 2023Review
- Developing Biomarkers for the Skin: Biomarkers for the Diagnosis and Prediction of Treatment Outcomes of Alzheimer's Disease.International journal of molecular sciences · 2023Article
- Orientational changes of white matter fibers in Alzheimer's disease and amnestic mild cognitive impairment.Human brain mapping · 2021Article
- A Bayesian hierarchical change point model with parameter constraints.Statistical methods in medical research · 2021Article
- Mulberry Fruit Cultivar 'Chiang Mai' Prevents Beta-Amyloid Toxicity in PC12 Neuronal Cells and in aMolecules (Basel, Switzerland) · 2020Article
- Article
- Kinetics and computational analysis of cholinesterase inhibition by REVERC3, a bisdemethoxycurcumin-richSAGE open medicine · 2020Article
- Hydrophilic fluorinated molecules for spectralScientific reports · 2018Article
- Alzheimer's disease and blood-based biomarkers - potential contexts of use.Neuropsychiatric disease and treatment · 2018Review
- Amyloid-Beta 1-42 Cross-Reactive Antibody Prevalent in Human Sera May Contribute to Intraneuronal Deposition of A-Beta-P-42.International journal of Alzheimer's disease · 2018Article
- Actin dynamics and cofilin-actin rods in alzheimer disease.Cytoskeleton (Hoboken, N.J.) · 2016Review
- Redox Proteomic Profiling of Specifically Carbonylated Proteins in the Serum of Triple Transgenic Alzheimer's Disease Mice.International journal of molecular sciences · 2016Article
- The elusive nature and diagnostics of misfolded Aβ oligomers.Frontiers in chemistry · 2015Review
- Circulating microRNAs in Alzheimer's disease: the search for novel biomarkers.Frontiers in molecular neuroscience · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease is the most common form of dementia affecting millions of individuals worldwide. It is currently diagnosed only via clinical assessments and confirmed by postmortem brain pathology. The development of validated biomarkers for Alzheimer's disease is essential to improve diagnosis and accelerate the development of new therapies. Biochemical and neuroimaging markers could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and be used to monitor efficacies of disease-modifying therapies. Cerebrospinal fluid (CSF) levels of Aβ40, Aβ42, total tau, and phosphorylated tau have diagnostic values in AD. Measurements of the above CSF markers in combination are useful in predicting the risk of progression from MCI to AD. New potential biomarkers are emerging, and CSF or plasma marker profiles may eventually become part of the clinician's toolkit for accurate AD diagnosis and management. These biomarkers along with clinical assessment, neuropsychological testing, and neuroimaging could achieve a much higher diagnostic accuracy for AD and related disorders in the future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.